HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.

Abstract
Allogeneic hematopoietic cell transplantation (HCT) is an increasingly widely used treatment modality in hematological malignancies. Alloreactivity mediated by donor T cells (and, in some settings, by donor natural killer cells) can produce durable immunologic control or eradication of residual malignancy after allogeneic HCT. However, graft-vs.-tumor (GVT) effects are variably effective and are often accompanied by deleterious alloreactivity against normal host tissue, manifesting as graft-vs.-host disease (GVHD). A major focus of current research in HCT is the separation of beneficial GVT effects from GVHD. Here we review a number of approaches currently under investigation to specifically augment GVT effects, including the identification of minor histocompatibility antigens (mHA), adoptive immunotherapy with tumor-specific or mHA-specific cytotoxic T lymphocytes, vaccination of the donor or recipient to stimulate tumor-specific immunity, and adoptive transfer of natural killer cells. In addition, we review strategies being investigated to specifically suppress GVHD while sparing GVT, including the manipulation and infusion of regulatory T cells, the use of novel pharmacologic and biologic agents, and the use of mesenchymal stem cells. Ultimately, advances in separation of GVT from GVHD will further enhance the potential of allogeneic HCT as a curative treatment for hematological malignancies.
AuthorsAndrew R Rezvani, Rainer F Storb
JournalJournal of autoimmunity (J Autoimmun) Vol. 30 Issue 3 Pg. 172-9 (May 2008) ISSN: 0896-8411 [Print] England
PMID18242060 (Publication Type: Journal Article, Review)
Chemical References
  • Minor Histocompatibility Antigens
Topics
  • Adoptive Transfer
  • Animals
  • Graft vs Host Disease (immunology, prevention & control)
  • Graft vs Tumor Effect (immunology)
  • Hematologic Neoplasms (immunology, therapy)
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Killer Cells, Natural (immunology, transplantation)
  • Mesenchymal Stem Cell Transplantation
  • Minor Histocompatibility Antigens (immunology)
  • T-Lymphocytes, Regulatory (immunology, transplantation)
  • Transplantation Conditioning
  • Transplantation Immunology
  • Transplantation, Homologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: